BOULDER, Colo.–(BUSINESS WIRE)–Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for severe, genetic neuromuscular and cardiac disorders for which there is significant unmet medical need, today reported financial results for the second quarter of 2023 and recent business highlights. “Edgewise has made significant progress in the first half of the year most notably with t
Click here to view original post
News
How Can the Body’s Immune Cells Cause Type 1 Diabetes?
It started with a love of caring for dogs and other animals. Click here to view original post
News
Think Bioscience Appoints Nicholas A. Saccomano, Ph.D., to its Board of Directors
Think Bioscience bolsters drug development expertise and deepens relationship with Colorado life science ecosystem following a $17M financing. BOULDER, Colo., Sept. 6, 2022 /PRNewswire/ — Think Bioscience (“Think”), a Boulder-based synthetic biology company focused on […]
News
FACIAL AESTHETICS CONTINUES ITS EXPANSION
Colorado medical spa of 30 years opens new clinic in Superior and announces further plans for expansion. SUPERIOR, Colo., July 20, 2023 /PRNewswire/ — Facial Aesthetics, Colorado’s premier medical spa of 30 years, opens its […]
